Ligand Pharmaceuticals announced a $739 million cash acquisition of XOMA Royalty Corporation, valuing the royalty aggregator at $39.00 per share. The deal includes a contingent value right that entitles XOMA shareholders to a share of any net proceeds from pending litigation, and is expected to close in the third quarter of 2026.
The transaction will add more than 120 commercial, clinical, and pre‑clinical assets to Ligand’s portfolio, including seven marketed products and 14 late‑stage candidates. Management expects the integration to deliver almost 100% operating‑expense synergies, as the XOMA portfolio requires no additional commercial, manufacturing, or clinical development infrastructure.
Financially, the acquisition is immediately accretive to Ligand’s adjusted earnings per share and is projected to lift the company’s 2026 revenue guidance to $270‑$310 million from the prior $245‑$285 million range. The new guidance also raises adjusted EPS expectations to $8.50‑$9.50 from the previous $8.00‑$9.00 band, reflecting confidence in the expanded portfolio and cost efficiencies.
Todd Davis, Ligand’s CEO, said, "The acquisition of XOMA Royalty presents a compelling opportunity for us to strengthen and diversify our portfolio across all stages of clinical development and accelerate our long‑term profitable growth. This acquisition will add seven marketed products and nearly double our portfolio of Phase 2 and 3 assets, which we believe will create significant value for our stockholders, all through a single transaction." He added, "We can absorb the XOMA portfolio with almost 100% synergies... there's no commercial infrastructure required, there's no manufacturing infrastructure, there's no clinical development infrastructure. So this is a highly efficient business model in general, and the operating expense essentially tied to the XOMA portfolio now largely goes away through that synergy realization." "The XOMA Royalty team has built a robust portfolio of complementary biopharmaceutical assets, and this acquisition will enable us to further grow and diversify in areas such as ophthalmology, oncology, CNS and rare diseases. With XOMA Royalty, we believe we will now be in an even stronger position to leverage our expertise and capital base to support broader patient access and advance late‑stage clinical programs in a way that enhances patient outcomes and improves lives."
The contingent value right is linked to a lawsuit against Johnson & Johnson’s Janssen unit over the commercialization of Tremfya. XOMA shareholders will receive 75% of the net proceeds from that litigation, providing a potential upside that investors have valued at roughly a 14% premium to the 30‑day volume‑weighted average price.
Investors have responded positively to the premium and the contingent value right, viewing the deal as a strategic consolidation that expands Ligand’s reach across ophthalmology, oncology, CNS, and rare diseases while delivering immediate earnings accretion and a higher revenue outlook.
revised_sentiment_rating":3} }
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.